Zepbound Is the First GLP-1 Approved for Sleep Apnea

Medically reviewed by a licensed healthcare professional. Last updated May 2026.

Key Takeaways

• Zepbound (tirzepatide) is the only GLP-1 the FDA has approved for moderate-to-severe obstructive sleep apnea in adults with obesity. The approval came on December 20, 2024.
• Wegovy and Ozempic are semaglutide, not tirzepatide, and are NOT approved for sleep apnea, even though they share the drug class.
• In the SURMOUNT-OSA trial, tirzepatide cut the apnea-hypopnea index by around 30 events per hour at the highest dose, about 62.8% relative to placebo.
• 50.2% of trial participants on existing CPAP therapy met disease-resolution criteria at 52 weeks on the highest dose.
• The American Academy of Sleep Medicine calls the approval a positive development but does not recommend dropping CPAP after starting Zepbound.
• The OSA indication opens a second insurance pathway for patients previously denied Zepbound on weight criteria alone.

I started looking into this the week after my brother-in-law texted me. He had been on Mounjaro for a year, his weight was down, his CPAP felt less essential, and he wanted to know if "the new sleep apnea approval" meant he could stop using the machine. The answer turned out to be more complicated than the headlines suggested. If you take any GLP-1 and you have sleep apnea, you should know what the FDA actually approved, what it did not, and how to talk to both your sleep doctor and your insurance company about it.

Here is the short version. On December 20, 2024, the FDA approved Zepbound (tirzepatide) as the first prescription medication for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This is the only GLP-1 with that indication. Wegovy and Ozempic are semaglutide, not tirzepatide. Same drug class, different molecule, different label. Mounjaro is tirzepatide too, but its label is type 2 diabetes, not OSA. The molecule and the indication both matter, especially when insurance is involved.

What the FDA actually approved

The approved indication is narrow on purpose. Zepbound is for moderate-to-severe OSA in adults with obesity (BMI of 30 or higher), as an adjunct to a reduced-calorie diet and increased physical activity. That is the approved indication. Three things to notice. Mild OSA is not covered. Adults with OSA who are not obese are not covered. And the FDA framed the drug as an adjunct, not a replacement, for the standard weight-management interventions.

I want to flag the BMI cutoff because it is doing more work than it looks. Zepbound was already approved for chronic weight management in adults with obesity. What the OSA approval changed is that patients who could not qualify on weight metrics alone, or whose insurance denied weight-loss coverage, now have a separate diagnostic basis. A 41-year-old with a BMI of 31 and severe OSA on a sleep study gets a different conversation with their plan than the same person without an OSA diagnosis.

What SURMOUNT-OSA actually showed

The approval came out of two phase 3 trials that ran in parallel and were published together in the New England Journal of Medicine in June 2024. They are usually called SURMOUNT-OSA Trial 1 and Trial 2. Same design, one variable.

The headline number you may have seen, 62.8% AHI reduction, came from Trial 2, the highest dose, the strongest signal. In plainer terms that is around 30 fewer apnea events per hour of sleep than placebo. Trial 1 was also positive, just smaller in magnitude.

Disease resolution is more interesting than the average. The trials defined resolution as an AHI under 5 events per hour, or an AHI between 5 and 14 with an Epworth Sleepiness Scale score of 10 or below (essentially OSA without daytime sleepiness). 42.2% of Trial 1 patients on the highest dose hit that bar. 50.2% of Trial 2 patients did. About half of treated patients on existing CPAP, at the highest tirzepatide dose, no longer met the criteria for moderate-to-severe OSA at one year. That is the result that pushed the FDA approval.

A few other endpoints moved the right direction in both trials. Body weight dropped about 18 to 20%. Hypoxic burden, an oxygen-deprivation measure that correlates with cardiovascular risk, decreased. So did C-reactive protein and systolic blood pressure. None of those are individually FDA-blessed claims, but they help explain why sleep doctors are cautiously enthusiastic.

What this means if you take Wegovy, Ozempic, or Mounjaro

Three patient questions come up constantly and the answers are not interchangeable.

If you take Mounjaro, you are taking tirzepatide. Same molecule as Zepbound. Different brand, different indication. Mounjaro is FDA-approved for type 2 diabetes. Some sleep doctors will still consider the SURMOUNT-OSA data relevant to their tirzepatide patients regardless of brand, and your insurer may or may not. If you have OSA and you want to use the SURMOUNT-OSA evidence for coverage, ask your prescriber whether moving from Mounjaro to Zepbound (with both an obesity diagnosis and an OSA diagnosis) gets you cleaner approval.

If you take Wegovy or Ozempic, you are taking semaglutide. Different molecule from tirzepatide. The FDA has approved Wegovy for chronic weight management and for cardiovascular risk reduction in adults with established heart disease and overweight or obesity (the SELECT trial, approved March 8, 2024). It has not approved semaglutide for OSA. Some clinicians prescribe it off-label in OSA patients who lose enough weight, but you do not have the FDA blessing or the 469-patient SURMOUNT-OSA dataset to lean on.

If you take a compounded GLP-1, you are in a separate gray zone. The FDA approval is brand-specific. A compounded version of tirzepatide is not Zepbound. Some compounding pharmacies are marketing the OSA approval as if it transfers; it does not, legally, and your insurance will not treat it that way.

Does this mean I can stop using my CPAP?

I asked my brother-in-law's sleep doctor this directly. The answer was no, with nuance.

The American Academy of Sleep Medicine called the Zepbound approval "a positive development for patients and clinicians" and emphasized that other treatment options for sleep apnea, including positive airway pressure therapy, oral appliance therapy, surgery, and upper airway stimulation, all remain valid. The AASM also flagged two things. Zepbound is only effective for OSA that is related to obesity. And weight loss has to be maintained for the benefit to hold.

Said another way, if your OSA is structural rather than weight-driven (jaw position, throat anatomy, large tonsils), tirzepatide will not fix it. And even if you respond well, going off Zepbound or rebounding back to your pre-treatment weight likely brings the apnea back too. Anyone planning to use the medication as a CPAP exit strategy needs a follow-up sleep study before discontinuing the machine, and even responders may need partial PAP support during the titration phase.

The insurance angle most patients miss

Here is the practical move. Plans without a dedicated GLP-1 weight-loss benefit routinely deny Zepbound when the only diagnosis is obesity, particularly when the employer has a weight-loss carve-out. The OSA indication is a separate medical-necessity pathway. If you have a recent sleep study showing moderate-to-severe OSA (AHI, REI, or RDI of 15 or higher) and a BMI of 30 or higher, you may qualify for coverage under the OSA indication even if your plan excludes weight-loss drugs. Bring three things to your prescriber visit: your sleep study report, your current BMI documented in the chart, and a written list of what you have already tried (CPAP adherence data is the strongest signal).

For Medicare and Medicaid patients, the OSA indication is shifting plan-by-plan as formularies update. UnitedHealthcare has a Zepbound-for-OSA-only prior authorization policy, and other commercial insurers are updating criteria plan by plan. If you were denied Zepbound for weight loss in 2024, re-submit under the OSA indication if you have a qualifying diagnosis. The denial letter from the first round becomes useful documentation rather than a closed case.

Curious whether your plan is moving on this? Start with our Zepbound cost and coverage guide, then check the state-by-state insurance breakdown for what your specific plan is doing on the GLP-1 class. If you are already on Zepbound and not seeing the response you expected, our Why am I not losing weight on Zepbound guide covers the most common reasons.

What to bring up at your next sleep doctor visit

Specifics work better than open-ended questions. If you want to seriously evaluate Zepbound for your OSA, ask:

1. Does my most recent sleep study qualify me as moderate or severe OSA under the AASM thresholds?
2. Given my current BMI, would the OSA indication strengthen my insurance case?
3. If I start Zepbound, what is your re-titration plan for my CPAP pressure as I lose weight?
4. At what point would you order a follow-up sleep study to see if CPAP can be reduced or discontinued?
5. If I respond and then stop the medication, what is the monitoring plan to catch OSA recurrence?

Sleep doctors and GLP-1 prescribers do not always coordinate. Bringing this list to both, and asking each to communicate with the other, beats waiting for the system to do it for you.

Frequently asked questions

Does Zepbound replace CPAP for sleep apnea? No. The AASM and Eli Lilly both treat Zepbound as a new option, not a replacement. About half of CPAP-using patients in SURMOUNT-OSA met OSA resolution criteria at 52 weeks, but AASM guidance supports follow-up sleep testing when reassessing OSA after non-PAP treatment or significant weight loss.

Is Wegovy approved for sleep apnea? No. Wegovy is semaglutide, and the FDA has not approved any semaglutide product for OSA. Only Zepbound (tirzepatide) has the OSA indication, granted December 20, 2024.

Will my insurance cover Zepbound for sleep apnea? Plan by plan. Insurers are updating formularies and prior-auth criteria throughout 2025 and 2026. If you have moderate-to-severe OSA documented by AHI, REI, or RDI of 15 or higher and a BMI of 30 or higher, the OSA indication may give your prescriber a separate medical-necessity pathway from weight-loss coverage. Bring your sleep study report to your prescriber to start the prior authorization.

How fast does Zepbound improve sleep apnea? Trial data measured outcomes at 52 weeks. Patients saw meaningful AHI reductions and 18 to 20% body weight loss across that year. Earlier benefit is plausible but not directly studied. Sleep doctors usually wait several months of sustained weight loss before considering reduced PAP pressures.

Can I take Zepbound for sleep apnea if I am not obese? The FDA indication requires a BMI of 30 or higher. Patients with a BMI under 30 do not meet the label criteria, even with severe OSA. Off-label prescribing is up to your clinician, and most insurers will not cover it.

What about central sleep apnea? SURMOUNT-OSA only studied obstructive sleep apnea (OSA). Central sleep apnea has different physiology and was not included in the trial. There is no FDA-approved Zepbound indication for central sleep apnea.

Sources

1. FDA Approves First Medication for Obstructive Sleep Apnea (FDA press announcement, December 20, 2024)
2. FDA approves Zepbound (tirzepatide) as the first and only prescription medicine for moderate-to-severe obstructive sleep apnea in adults with obesity (Eli Lilly press release, December 20, 2024)
3. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (New England Journal of Medicine, June 2024; SURMOUNT-OSA primary publication)
4. Zepbound approval for sleep apnea: AASM statement (American Academy of Sleep Medicine)
5. Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity (Novo Nordisk, March 8, 2024; SELECT trial)